These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.

The firm will use the funds to further develop its AI-driven image analysis solutions, which extract actionable information from CT, PET, and MRI scans.